221 related articles for article (PubMed ID: 22806700)
1. [Scleromyxedema. A chronic progressive systemic disease].
Kreuter A; Stücker M; Kolios AG; Altmeyer P; Möllenhoff K
Z Rheumatol; 2012 Aug; 71(6):504-14. PubMed ID: 22806700
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
3. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
4. [Scleromyxedema].
Neufeld M; Sunderkötter C; Moritz RKC
Hautarzt; 2018 Nov; 69(11):916-921. PubMed ID: 30135969
[TBL] [Abstract][Full Text] [Related]
5. An unusual presentation of scleromyxedema as inflammatory myopathy.
Vysakha KV; Poyuran R; Nair SS; Nair M
Acta Myol; 2019 Mar; 38(1):13-16. PubMed ID: 31309176
[TBL] [Abstract][Full Text] [Related]
6. [Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].
Topf S; Simon M; Schell H; Lüftl M
Hautarzt; 2007 Jun; 58(6):525-8. PubMed ID: 17165069
[TBL] [Abstract][Full Text] [Related]
7. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin.
Kim S; Park TH; Lee SM; Kim YH; Cho MK; Whang KU; Kim HS
Dermatol Ther; 2020 May; 33(3):e13378. PubMed ID: 32250023
[TBL] [Abstract][Full Text] [Related]
8. Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.
Delyon J; Bézier M; Rybojad M; Brière J; Validire P; Bagot M; Janin A; Battistella M
Virchows Arch; 2013 Jun; 462(6):679-83. PubMed ID: 23681113
[TBL] [Abstract][Full Text] [Related]
9. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.
Rongioletti F; Merlo G; Cinotti E; Fausti V; Cozzani E; Cribier B; Metze D; Calonje E; Kanitakis J; Kempf W; Stefanato CM; Marinho E; Parodi A
J Am Acad Dermatol; 2013 Jul; 69(1):66-72. PubMed ID: 23453242
[TBL] [Abstract][Full Text] [Related]
10. Acute Encephalitic Syndrome Induced by Scleromyxedema.
Magira EE; Malouchou A; Karathanasi V; Mavropoulou N; Siempos II; Vourlakou C; Sykaras A; Anastasiadis G
Am J Med Sci; 2020 Aug; 360(2):192-195. PubMed ID: 32540147
[TBL] [Abstract][Full Text] [Related]
11. [Scleromyxedema].
Sunderkötter C; Bruns T; Pfeiffer C
Dermatologie (Heidelb); 2024 Mar; 75(3):225-231. PubMed ID: 38363313
[TBL] [Abstract][Full Text] [Related]
12. Scleromyxedema in a 21 year old female patient with acute lymphoblastic leukemia: a case report.
Rabee H; Tayem L; Gharbeyah M; Abugaber D
BMC Dermatol; 2020 Dec; 20(1):18. PubMed ID: 33276772
[TBL] [Abstract][Full Text] [Related]
13. Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema.
Ataergin S; Arpaci F; Demiriz M; Ozet A
Am J Clin Dermatol; 2008; 9(4):271-3. PubMed ID: 18572979
[TBL] [Abstract][Full Text] [Related]
14. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
15. Resident Rounds part III: scleromyxedema: a rare disorder associated with a monoclonal gammopathy.
Mandell JA; Glick JB; Kaur RR
J Drugs Dermatol; 2014 May; 13(5):619-20. PubMed ID: 24809891
[TBL] [Abstract][Full Text] [Related]
16. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema.
Binitha MP; Nandakumar G; Thomas D
Indian J Dermatol Venereol Leprol; 2008; 74(3):248-50. PubMed ID: 18583794
[TBL] [Abstract][Full Text] [Related]
17. Atypical discrete papular lichen myxedematosus associated with monoclonal gammopathy: report of four cases and review of the literature.
Hermans C; Goldscheider I; Ruzicka T; Rongioletti F
J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2048-2051. PubMed ID: 27422288
[TBL] [Abstract][Full Text] [Related]
18. Scleromyxedema.
Hoffmann JHO; Enk AH
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1449-1467. PubMed ID: 33373143
[TBL] [Abstract][Full Text] [Related]
19. [Scleromyxedema].
Kukova G; Bruch-Gerharz D; Gensch K; Ruzicka T; Reifenberger J
Hautarzt; 2006 Apr; 57(4):326-7. PubMed ID: 16523272
[No Abstract] [Full Text] [Related]
20. Scleromyxedema with histology resembling granuloma annulare.
Mullangi S; Granter SR; Laubach JP; Lipworth AD
Dermatol Online J; 2014 Dec; 21(3):. PubMed ID: 25780962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
